国家医保局连开座谈会释放哪些新信号

Core Viewpoint - The future value-based purchasing of medical insurance will focus on the real-world effectiveness of innovative drugs and devices rather than solely on laboratory data provided at the time of market entry [1][2]. Group 1: Policy and Evaluation Framework - The National Healthcare Security Administration (NHSA) is implementing a comprehensive value evaluation for innovative drugs and devices as part of new policies to support high-quality development [1][3]. - The NHSA is conducting a series of discussions to gather insights on how real-world data can serve the comprehensive value evaluation of drugs and devices [1][2]. - A systematic and complete evaluation framework is needed to scientifically assess the comprehensive value of medical products, addressing issues such as where funds are allocated and whether expenditures are justified [2][3]. Group 2: Stages of Value Evaluation - The comprehensive value evaluation of drugs will occur in three stages: pre-market, post-market before insurance entry, and post-insurance entry [2][3]. - Pre-market evaluation will involve collecting clinical data for drugs not yet available in the domestic market but used in specific regions, serving as a basis for market entry and insurance inclusion [2]. - Post-market evaluation will assess drugs based on safety, efficacy, economic viability, equity, accessibility, and innovation, comparing them with similar products to determine insurance inclusion [3]. Group 3: Implications for the Industry - The establishment of a comprehensive value evaluation system is expected to avoid internal competition among innovations and guide the rational allocation of medical resources [4][5]. - The NHSA's initiative signals a shift from a low-price strategy to a more value-based approach in determining insurance payment standards for innovative drugs [3][5]. - Collaboration opportunities may arise for commercial health insurance companies in areas such as innovative drug directories and one-stop settlement with basic medical insurance [5].